Retrospective multicenter study demonstrates substantial blood pressure reductions in resistant hypertension, indicating renal denervation is an effective adjunctive therapy.
Key Points
To evaluate the clinical efficacy and safety of catheter-based renal denervation in reducing blood pressure and medication burden among patients with resistant hypertension.
Retrospective, multicenter, real-world study of N=26 consecutive patients across 21 tertiary care centers in India.
Follow-up evaluations occurred at discharge and at 1, 3, 6, and 12 months after catheter-based renal denervation.
Primary endpoint was office blood pressure change at 12 months; secondary endpoints evaluated antihypertensive medication class count and procedural safety.
Mean office systolic and diastolic blood pressure dropped from 186.2 ± 18.8 / 98.7 ± 25.3 mm Hg at baseline to 121.7 ± 10.5 / 75.9 ± 4.7 mm Hg at 12 months, reflecting reductions of 63.4 mm Hg and 24.7 mm Hg (both P < 0.001).
Antihypertensive medication burden significantly declined from a mean of 5.12 ± 1.70 classes at baseline to 2.00 ± 0.80 classes at 12 months (P < 0.001).
No major periprocedural complications occurred, with one access-site superficial femoral artery complication successfully managed via covered stent implantation.